Table 2. Selected trials on first-line treatment in advanced pancreatic cancers.
| Trial | Types of trial | N | Intervention | Primary endpoint | RR (%) | mDFS (months) | mOS (months) | Result |
|---|---|---|---|---|---|---|---|---|
| Burris III et al [33] | RCT phase III | 126 | G vs. bolus 5-FU |
‘Clinical benefit’ | 5.4 vs 1 | 2.33 vs 0.92 | 5.65 vs 4.4 | Achieved primary end point |
| National Cancer Institute of Canada Clinical Trials Group [71] | RCT phase III | 569 | G plus erlotinib vs. gemcitabine |
OS | 8.6 vs 8 | 3.75 vs 3.55 | 6.24 vs 5.91 | Achieved primary end point, though limited clinical relevance |
| PRODIGE 4-ACCORD 11 [22] | RCT phase III | 342 | FOLFIRINOX vs. G |
OS | 31.6 vs 9.4 | 6.4 vs 3.3 | 11.1 vs 6.8 | Achieved primary end point |
| MPACT [23] | RCT phase III | 861 | G- nab-paclitaxel vs. gemcitabine |
OS | 23 vs 7 | 5.5 vs 3.7 | 8.5 vs 6.7 | Achieved primary end point |
N, Total no of patients; RR, Response rates; mDFS, Median disease-free survival; mOS, Median overall survival; RCT, Randomized clinical trial; OS, Overall survival; G, Gemcitabine; 5 FU, 5 Fluorouracil; FOLFIRINOX, 5-fluorouracil-leucovorin-irinotecan-oxaliplatin